Since the mid-April pricing of Hookipa Pharma Inc.'s IPO, the New York-based firm has endured a bumpy ride on Wall Street, with shares sliding steadily since backers bought 6 million at $14 each for $84 million in proceeds. But among those keeping the faith are analysts at Evercore ISI, who recently hosted a webinar to highlight the research ongoing at Hookipa, which Ravi Mehrotra called "one of the most interesting companies we've come across."